Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Total Liabilities : ¥5,206 Mil (As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Total Liabilities?

Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2025 was ¥5,206 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's quarterly Total Liabilities declined from Sep. 2024 (¥5,906.89 Mil) to Dec. 2024 (¥5,141.40 Mil) but then increased from Dec. 2024 (¥5,141.40 Mil) to Mar. 2025 (¥5,205.77 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual Total Liabilities declined from Dec. 2022 (¥8,406.56 Mil) to Dec. 2023 (¥7,215.04 Mil) and declined from Dec. 2023 (¥7,215.04 Mil) to Dec. 2024 (¥5,141.40 Mil).

Shenzhen Hepalink Pharmaceutical Group Co Total Liabilities Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Total Liabilities Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

7,336.91

7,584.86

8,406.56

7,215.04

5,141.40

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															6,736.46	6,364.09	5,906.89	5,141.40	5,205.77

Shenzhen Hepalink Pharmaceutical Group Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3699.237	+	(1138.818	+	279.667
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	23.681)
	=	5,141

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	17343.524	-	12202.121
	=	5,141

Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3873.968	+	(1029.265	+	279.143
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	23.681)
	=	5,206

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	17545.802	-	12340.036
	=	5,206

Shenzhen Hepalink Pharmaceutical Group Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (SZSE:002399) » Definitions » Total Liabilities

Traded in Other Exchanges

09989:Hong Kong

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.

Executives

Zhang Ping	Director
Li Li	Director
Kong Yun	Executives
Li Tan	Directors, executives

Shenzhen Hepalink Pharmaceutical Group Co Headlines

No Headlines